Difference between revisions of "Daratumumab and vorhyaluronidase (Darzquro)"
Jump to navigation
Jump to search
m |
m |
||
| Line 21: | Line 21: | ||
[[Category:Light-chain (AL) amyloidosis medications]] | [[Category:Light-chain (AL) amyloidosis medications]] | ||
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] | ||
| − | + | [[Category:Janssen product]] | |
[[Category:PMDA approved in 2021]] | [[Category:PMDA approved in 2021]] | ||
Revision as of 01:05, 7 June 2023
General information
Class/mechanism: Anti-CD38 antibody, human monoclonal IgG1 kappa. Daratumumab binds to CD38 and causes apoptosis in CD38-expressing cells via Fc mediated cross-linking, complement-dependent cytotoxicity (CDC), antibody-dependent cell mediated cytotoxicity (ADCC), and antibody dependent cellular phagocytosis (ADCP). CD38 is present on the cell surface of multiple myeloma (MM), plasma leukemia, and natural killer (NK) cells.
Diseases for which it is used
History of changes in PMDA indication
- 2021-03-23: Newly indicated for the treatment of multiple myeloma.
- 2021-08-25: new indication and a new dosage for the treatment of systemic AL amyloidosis.
Also known as
- Generic name: Daratumumab and vorhyaluronidase alfa
- Brand name: Darzquro